Hormone Replacement Therapy and Glycemic Control: Evidence from Observational Studies and Randomized Clinical Trials

We thank Aguilar-Salinas et al. (1) for their interest in our paper (2), and we agree that the cross-sectional associations between hormone replacement therapy (HRT) and lower HbA1c levels we reported do not establish causality. We concur with the need of long-term clinical trials among women with diabetes in order to understand whether and to what extent HRT may improve glycemic control. However, our findings are consistent with small and short-term randomized trials in women with diabetes (3,4,5). We demonstrated a number of differences between HRT users and nonusers in our report and went …

[1]  W. Sutherland,et al.  The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial. , 2001, Archives of internal medicine.

[2]  Jennifer Y. Liu,et al.  Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. , 2001, Diabetes care.

[3]  J. Connell,et al.  The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  K. Friday,et al.  Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  C. Aguilar-Salinas,et al.  Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control. , 2001, The Israel Medical Association journal : IMAJ.

[6]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[7]  M. Frölich,et al.  Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM , 1997, Diabetologia.

[8]  P. Björntorp,et al.  Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[9]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[10]  B. Walsh,et al.  Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women , 1994, Obstetrics and gynecology.